LXRX News and Press, Lexicon Pharmaceuticals Inc. From 02/28/22

Lexicon Pharmaceuticals press release (NASDAQ:LXRX): Q4 GAAP EPS of -$0.17 beats by $0.01. Revenue of $0.01M (-95.0% Y/Y). For further details see: Lexicon Pharmaceuticals GAAP EPS of -$0.17 beats by $0.01, revenue of $0.01M

THE WOODLANDS, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today reported financial results for the three months and full-year ended December 31, 2021 and provided an update on key milestones. “We remain focused on advancing sot...

Resubmission to Correct Recently-Identified Technical Issue Conference Call and Webcast at 8:00 am Eastern Time THE WOODLANDS, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the voluntary withdrawal and...

THE WOODLANDS, Texas, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2021 financial results on Monday, February 28, 2022 before the markets open. Management will conduct a conference call and live webcast at 8:...

NDA submitted for sotagliflozin in heart failure with an expected launch in 2H 2022, if approved LX9211 neuropathic pain Phase 2 studies expected to read out in 1H 2022 THE WOODLANDS, Texas, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)...

THE WOODLANDS, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the 40 th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30...

THE WOODLANDS, Texas, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of sotagliflozin to reduce the risk of c...

The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...

THE WOODLANDS, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its virtual participation in the following conferences: Jefferies London Healthcare Conference, taking place November 16-19, 2021 Piper Sandler 33 rd Annu...

Lexicon Pharmaceuticals (NASDAQ:LXRX) is trading ~11.8% higher in the pre-market after announcing a new analysis demonstrating the clinical benefits of diabetes therapy sotagliflozin in heart failure and blood glucose control. The pooled analysis was based on data from SOLOIST ...